A Study of JNJ-64281802 for the Prevention of Dengue Infection

Inclusion Criteria:

• Healthy on the basis of physical examination, medical history, and vital signsperformed at screening. If there are abnormalities, the participant may be includedonly if the investigator judges the abnormalities to be not clinically relevant.This determination must be recorded in the participant's source documents

• Must have a body mass index (BMI, weight in kilogram [kg] divided by the square ofheight in meters) between 18.0 and 35.0 kilograms per meter square (kg/m^2)inclusive, and a body weight of greater than or equal to (>=) 40.0 kg at screening

• A woman must have a negative highly sensitive urine pregnancy test at screening

• A male participant must agree not to donate sperm for the purpose of reproductionduring the study and for >= 90 days after receiving the last dose of studyintervention

• Must sign an informed consent form (ICF) (or their legally acceptable representativemust sign) indicating that the participant understands the purpose of, andprocedures required for, the study and is willing to participate in the study

Exclusion Criteria:

• Having any dengue virus (DENV)-associated clinical signs and symptoms

• Known allergies, hypersensitivity, or intolerance to JNJ-64281802 or its excipients

• Any clinically relevant skin disease (as assessed by the investigator) in the past 3months such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, foodallergy, and urticaria

• Reduced immune function to be: (a) Known or suspected congenital or acquiredimmunodeficiency; or (b) receipt of immunomodulation therapy within the last 6months (such as anticancer chemotherapy or radiation therapy)

• Received an investigational intervention (including investigational vaccines otherthan a corona virus disease 2019 [COVID-19] vaccine) or used an invasiveinvestigational medical device within 3 months before the planned first dose ofstudy intervention or received an investigational biologic product within 3 monthsprior to enrollment or 5 half-lives, whichever is longer, before the planned firstdose of study intervention, or is currently enrolled in an investigational study